Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zidovudine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Zidovudine | DRUG | - |
| Zalcitabine | DRUG | - |
| Didanosine | DRUG | - |
| Ganciclovir | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. * CD4 count 100 - 500 cells/mm3.
Top 20 of 28 competitors
Zidovudine is used for HIV Infections and Cytomegalovirus Infections. It is a small molecule being developed by Roche Holding AG (RHHBY) for the Infectious Disease therapeutic area. The drug is currently in Phase 1 clinical development, with one completed Phase 1 trial and one completed Phase 3 trial.
Zidovudine is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is a small molecule intended for the treatment of HIV Infections and Cytomegalovirus Infections. It is currently in Phase 1 clinical development.
Zidovudine is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for HIV Infections and Cytomegalovirus Infections. The development program includes one completed Phase 1 trial and one completed Phase 3 trial.
Zidovudine has been studied in two completed trials. NCT00002096 is a Phase 1 pharmacokinetic study in HIV-positive subjects of oral ganciclovir with zidovudine and didanosine, enrolling 24 participants. NCT00002117 is a Phase 3 randomized, open-label study of alternative treatment combinations of dideoxycytidine and zidovudine, enrolling 528 participants.
Zidovudine is also known as AZT, as referenced in the clinical trial NCT00002117, which evaluates zidovudine (AZT) in combination with other antiretrovirals. The drug is being developed by Roche Holding AG for HIV Infections and Cytomegalovirus Infections.